211 related articles for article (PubMed ID: 28367845)
1. One-Year Efficacy and Safety of Evolocumab in Japanese Patients - A Pooled Analysis From the Open-Label Extension OSLER Studies.
Hirayama A; Yamashita S; Inomata H; Kassahun H; Cyrille M; Ruzza A; Yoshida M; Kiyosue A; Ma Y; Teramoto T
Circ J; 2017 Jun; 81(7):1029-1035. PubMed ID: 28367845
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Treatment With Evolocumab Among Japanese Patients - Final Report of the OSLER Open-Label Extension Studies.
Hirayama A; Yamashita S; Ruzza A; Inomata H; Cyrille M; Lu C; Hamer AW; Yoshida M; Kiyosue A; Teramoto T
Circ J; 2019 Apr; 83(5):971-977. PubMed ID: 30930429
[TBL] [Abstract][Full Text] [Related]
3. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Kassahun H; Ruzza A; Ma Y; Somaratne R; Raal FJ
JAMA Cardiol; 2017 Jun; 2(6):598-607. PubMed ID: 28291870
[TBL] [Abstract][Full Text] [Related]
4. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study.
Hirayama A; Honarpour N; Yoshida M; Yamashita S; Huang F; Wasserman SM; Teramoto T
Circ J; 2014; 78(5):1073-82. PubMed ID: 24662398
[TBL] [Abstract][Full Text] [Related]
5. Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies.
Cho L; Dent R; Stroes ESG; Stein EA; Sullivan D; Ruzza A; Flower A; Somaratne R; Rosenson RS
Cardiovasc Drugs Ther; 2018 Aug; 32(4):365-372. PubMed ID: 30073585
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
Koren MJ; Giugliano RP; Raal FJ; Sullivan D; Bolognese M; Langslet G; Civeira F; Somaratne R; Nelson P; Liu T; Scott R; Wasserman SM; Sabatine MS;
Circulation; 2014 Jan; 129(2):234-43. PubMed ID: 24255061
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia.
Hovingh GK; Raal FJ; Dent R; Stefanutti C; Descamps O; Masana L; Lira A; Bridges I; Coll B; Sullivan D
J Clin Lipidol; 2017; 11(6):1448-1457. PubMed ID: 29066265
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia.
Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Ruzza A; Ma Y; Hamer AW; Wasserman SM; Raal FJ
J Am Coll Cardiol; 2019 Oct; 74(17):2132-2146. PubMed ID: 31648705
[TBL] [Abstract][Full Text] [Related]
9. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
[TBL] [Abstract][Full Text] [Related]
10. Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial.
Koba S; Inoue I; Cyrille M; Lu C; Inomata H; Shimauchi J; Kajinami K
J Atheroscler Thromb; 2020 May; 27(5):471-484. PubMed ID: 31748467
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
O'Donoghue ML; Giugliano RP; Wiviott SD; Atar D; Keech A; Kuder JF; Im K; Murphy SA; Flores-Arredondo JH; López JAG; Elliott-Davey M; Wang B; Monsalvo ML; Abbasi S; Sabatine MS
Circulation; 2022 Oct; 146(15):1109-1119. PubMed ID: 36031810
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Sabatine MS; Giugliano RP; Wiviott SD; Raal FJ; Blom DJ; Robinson J; Ballantyne CM; Somaratne R; Legg J; Wasserman SM; Scott R; Koren MJ; Stein EA;
N Engl J Med; 2015 Apr; 372(16):1500-9. PubMed ID: 25773607
[TBL] [Abstract][Full Text] [Related]
13. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
Stroes E; Colquhoun D; Sullivan D; Civeira F; Rosenson RS; Watts GF; Bruckert E; Cho L; Dent R; Knusel B; Xue A; Scott R; Wasserman SM; Rocco M;
J Am Coll Cardiol; 2014 Jun; 63(23):2541-2548. PubMed ID: 24694531
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
[TBL] [Abstract][Full Text] [Related]
15. Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
Boccara F; Kumar PN; Caramelli B; Calmy A; López JAG; Bray S; Cyrille M; Rosenson RS;
J Am Coll Cardiol; 2020 May; 75(20):2570-2584. PubMed ID: 32234462
[TBL] [Abstract][Full Text] [Related]
16. A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk.
Kiyosue A; Honarpour N; Kurtz C; Xue A; Wasserman SM; Hirayama A
Am J Cardiol; 2016 Jan; 117(1):40-7. PubMed ID: 26547291
[TBL] [Abstract][Full Text] [Related]
17. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.
Koren MJ; Lundqvist P; Bolognese M; Neutel JM; Monsalvo ML; Yang J; Kim JB; Scott R; Wasserman SM; Bays H;
J Am Coll Cardiol; 2014 Jun; 63(23):2531-2540. PubMed ID: 24691094
[TBL] [Abstract][Full Text] [Related]
18. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy.
Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
Clin Cardiol; 2014 Mar; 37(3):131-9. PubMed ID: 24477778
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON.
Teramoto T; Kiyosue A; Ishigaki Y; Harada-Shiba M; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
J Cardiol; 2019 Mar; 73(3):218-227. PubMed ID: 30509509
[TBL] [Abstract][Full Text] [Related]
20. Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT.
Santos RD; Ruzza A; Hovingh GK; Stefanutti C; Mach F; Descamps OS; Bergeron J; Wang B; Bartuli A; Buonuomo PS; Greber-Platzer S; Luirink I; Bhatia AK; Raal FJ; Kastelein JJP; Wiegman A; Gaudet D
Lancet Diabetes Endocrinol; 2022 Oct; 10(10):732-740. PubMed ID: 36075246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
